8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Anne Boerekamps, Thomas Vanwolleghem, Marc van der Valk, Guido E. van den Berk, Marjo van Kasteren, Dirk Posthouwer, Anthonius S. M. Dofferhoff, Bart van Hoek, Dewkoemar Ramsoekh, Jelle Koopsen, Janke Schinkel, Eric Florence, Joop E. Arends, Bart J. Rijnders

Research output: Contribution to journalComment/Letter to the editorAcademic

Original languageEnglish
Pages (from-to)554-557
JournalJournal of Hepatology
Volume70
Issue number3
DOIs
Publication statusPublished - 2019

Cite this

Boerekamps, A., Vanwolleghem, T., van der Valk, M., van den Berk, G. E., van Kasteren, M., Posthouwer, D., ... Rijnders, B. J. (2019). 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology, 70(3), 554-557. https://doi.org/10.1016/j.jhep.2018.10.032
Boerekamps, Anne ; Vanwolleghem, Thomas ; van der Valk, Marc ; van den Berk, Guido E. ; van Kasteren, Marjo ; Posthouwer, Dirk ; Dofferhoff, Anthonius S. M. ; van Hoek, Bart ; Ramsoekh, Dewkoemar ; Koopsen, Jelle ; Schinkel, Janke ; Florence, Eric ; Arends, Joop E. ; Rijnders, Bart J. / 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). In: Journal of Hepatology. 2019 ; Vol. 70, No. 3. pp. 554-557.
@article{743ac90020044f38abe81b182b6c9a87,
title = "8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)",
author = "Anne Boerekamps and Thomas Vanwolleghem and {van der Valk}, Marc and {van den Berk}, {Guido E.} and {van Kasteren}, Marjo and Dirk Posthouwer and Dofferhoff, {Anthonius S. M.} and {van Hoek}, Bart and Dewkoemar Ramsoekh and Jelle Koopsen and Janke Schinkel and Eric Florence and Arends, {Joop E.} and Rijnders, {Bart J.}",
year = "2019",
doi = "10.1016/j.jhep.2018.10.032",
language = "English",
volume = "70",
pages = "554--557",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

Boerekamps, A, Vanwolleghem, T, van der Valk, M, van den Berk, GE, van Kasteren, M, Posthouwer, D, Dofferhoff, ASM, van Hoek, B, Ramsoekh, D, Koopsen, J, Schinkel, J, Florence, E, Arends, JE & Rijnders, BJ 2019, '8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)' Journal of Hepatology, vol. 70, no. 3, pp. 554-557. https://doi.org/10.1016/j.jhep.2018.10.032

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). / Boerekamps, Anne; Vanwolleghem, Thomas; van der Valk, Marc; van den Berk, Guido E.; van Kasteren, Marjo; Posthouwer, Dirk; Dofferhoff, Anthonius S. M.; van Hoek, Bart; Ramsoekh, Dewkoemar; Koopsen, Jelle; Schinkel, Janke; Florence, Eric; Arends, Joop E.; Rijnders, Bart J.

In: Journal of Hepatology, Vol. 70, No. 3, 2019, p. 554-557.

Research output: Contribution to journalComment/Letter to the editorAcademic

TY - JOUR

T1 - 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

AU - Boerekamps, Anne

AU - Vanwolleghem, Thomas

AU - van der Valk, Marc

AU - van den Berk, Guido E.

AU - van Kasteren, Marjo

AU - Posthouwer, Dirk

AU - Dofferhoff, Anthonius S. M.

AU - van Hoek, Bart

AU - Ramsoekh, Dewkoemar

AU - Koopsen, Jelle

AU - Schinkel, Janke

AU - Florence, Eric

AU - Arends, Joop E.

AU - Rijnders, Bart J.

PY - 2019

Y1 - 2019

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060958739&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30527953

U2 - 10.1016/j.jhep.2018.10.032

DO - 10.1016/j.jhep.2018.10.032

M3 - Comment/Letter to the editor

VL - 70

SP - 554

EP - 557

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -